Last reviewed · How we verify
Placebo for risendronate
This is a placebo, meaning it has no active pharmacological effect.
This is a placebo, meaning it has no active pharmacological effect. Used for Treatment of osteoporosis.
At a glance
| Generic name | Placebo for risendronate |
|---|---|
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological systems or receptors, and its effects are purely psychological or due to the natural course of the disease. Placebos are often used as a control group in clinical trials to compare the efficacy of active treatments.
Approved indications
- Treatment of osteoporosis
Common side effects
- No adverse events
Key clinical trials
- A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) (PHASE3)
- Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids (PHASE3)
- Post-menopausal Women Osteoporosis(Phase III) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for risendronate CI brief — competitive landscape report
- Placebo for risendronate updates RSS · CI watch RSS
- Amgen portfolio CI